Cardinal Health Stock News

SAN FRANCISCO , March 3, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "N95 Masks - Global Market Trajectory & Analytics" . The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What''s New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research Platform Complimentary updates for one year Edition: 2; Released: February 2022 Executive Pool: 382 Companies: 68 - Players covered include 3M Company; Alpha Pro Tech Inc; Ansell ltd; Cambridge Mask Co; Cardinal Health, Inc; Honeywell International Inc; JIANGSU TEYIN IMP. & EXP. CO., LTD; Kimberly-Clark Worldwide, Inc; Makrite; Moldex-Metric, Inc; Prestige Ameritech; Reckitt Benckiser; Shanghai Dasheng; The Gerson Company; Vogmask and Others.

ET Intelligence Group: The Street frowned upon Indian drug major Biocon''s move to buy the biologic business of its US business partner Viatris through its subsidiary Biocon Biologics (BBL). The Biocon stock lost 11.2% on Monday as analysts were concerned about high deal valuations, an increase in Biocon''s debt burden and execution risks in a still-emerging and complex area of biosimilars.The $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of Biocon. With this deal, BBL is buying out the biosimilar portfolio of its long-time collaborator Mylan that merged with Pfizer''s Upjohn business to become Viatris. The acquisition will allow BBL to acquire regulatory, supply chain and commercialisation capabilities in the developed markets. It also gets rights to key in-licensed therapies including biosimilar Adalimumab (used to treat autoimmune conditions) and an option to acquire the Viatris''s rights for biosimilar Aflibercept (used to treat macular disorders) at a cost of $175 million. 89914048BBL has a portfolio of 20 biosimilars - out of which seven have been commercialised.For the December quarter, it earned revenues of ₹981 crore, 28% higher than a year ago, with a core operating profit (Ebitda) margin of 38%.

Drug distributors McKesson, AmerisourceBergen and Cardinal Health are part of the settlement.

The three largest pharmaceutical distributors have approved the $19.5 billion settlement with states and municipalities over expenses of the opioid crisis.

Johnson & Johnson (NYSE: JNJ ) shares are trading higher Friday after the company agreed to finalize a proposed $26 billion settlement resolving more than 3,000 lawsuits, mainly by state and local governments, seeking to hold it and three other companies responsible for the opioid abuse crisis. The other companies are distributors McKesson Corp (NYSE: MCK ), AmerisourceBergen Corp (NYSE: ABC ) and Cardinal Health Inc (NYSE: CAH ). Johnson & Johnson was up 4.97% at $166 Friday afternoon at publication. See Also: Drug Distributors, JNJ Agree To Settle $26B Opioid Lawsuits Johnson & Johnson Daily Chart Analysis The stock recently bounced off support in a sideways channel and has been pushing higher, now nearing the resistance level of the channel. Support was found near … Full story available on Benzinga.com

Drugmaker Johnson & Johnson and three major distributors finalized nationwide settlements over their role in the opioid addiction crisis Friday, an announcement that clears the way for $26 billion to flow to nearly every state and local government in the U.S. Taken together, the settlements are the largest to date among the many opioid-related cases that have been playing out across the country. They''re expected to provide a significant boost to efforts aimed at reversing the crisis in places that have been devastated by it, including many parts of rural America. Johnson & Johnson, AmerisourceBergen, Cardinal Health and McKesson announced the settlement plan last year, but the deal was contingent on getting participation from a critical mass of state and local governments. Friday was the deadline for the companies to announce whether they felt enough governments had committed to participate in the settlement and relinquish the right to sue. The four companies notified lawyers for the governments in the case that their thresholds were met, meaning money could start flowing to communities by April. "We''re never going to have enough money to immediately cure this problem," said Joe Rice, one of the lead lawyers who represented local governments in the litigation that led to the settlement. "What we''re trying to do is give a lot of small communities a chance to try to change some of their problems." While none of the settlement money will go directly to victims of opioid addiction or their survivors, the vast majority of it is required to be used to deal with the epidemic.

Distributors McKesson Corporation (NYSE: MCK ), AmerisourceBergen Corp (NYSE: ABC ), Cardinal Health Inc (NYSE: CAH ), and Johnson & Johnson (NYSE: JNJ ) have agreed to finalize a proposed $26 billion settlement resolving claims by states and local governments regarding the opioid epidemic. The deal aims to resolve more than 3,000 lawsuits, mainly by state and local governments seeking to hold the companies responsible for … Full story available on Benzinga.com

The three distributors, McKessen, AmerisourceBergen and Cardinal Health, each "independently determined" that enough states and litigating political subdivisions had signed on to advance the agreement to pay out $19.5 billion over 18 years to thousands of plaintiffs, according to a joint press release from the companies.

BET À DAY Drugmaker Johnson & Johnson and three major distributors (McKessen, AmerisourceBergen and Cardinal Health) confirmed on Friday that they will pay $24.5 billion to end more than 3,000 lawsuits by US states and thousands of communities. In a joint statement, the distributors said they had independently determined that there was “sufficient participation from […] The post Opiate crisis: J&J and 3 distributors agree to pay nearly 25 billion dollars first appeared on The Bobr Times .

AmerisourceBergen, Cardinal Health and McKesson said they would proceed with a settlement of the majority of the opioid lawsuits filed by state and local governments in the U.S.

AmerisourceBergen, Cardinal Health and McKesson said they agreed to proceed with a settlement of the majority of the opioid lawsuits filed by state and local governments in the U.S.

AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) announced on Friday their decision to proceed with more than $19B worth of agreement to settle claims over their role…

Global Medical Corrugated Tubing Market Research Report provides key analysis on the market status of the Medical Corrugated Tubing with the best facts and figures, meaning, definition, SWOT analysis, expert opinions, and the latest developments across the globe. The report